2023
DOI: 10.1007/s40487-023-00235-6
|View full text |Cite
|
Sign up to set email alerts
|

The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer

Abstract: Introduction The immunomodulatory impact of corticosteroids and concurrent chemotherapy is poorly understood within triple-negative breast cancer (TNBC). On a biochemical level, steroids have been linked to the signaling of chemotherapy-resistant pathways. However, on a clinical level, steroids play an essential role in chemotherapy tolerance through the prevention of chemotherapy-induced nausea and vomiting (CINV) and hypersensitivity reactions. Given these conflicting roles, we wanted to evaluat… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 55 publications
0
1
0
Order By: Relevance
“…Dexamethasone, an immunosuppressive corticosteroid, was given to all patients receiving Docetaxel in the FinHER trial (16). Although dexamethasone is a lymphodepleting agent, it is reported to have no significant impact on the clinical outcome of neoadjuvant TNBC patients retrospectively (54). Corticosteroid administration is not considered when characterizing treatment regimens during GEO dataset integration.…”
Section: Discussionmentioning
confidence: 99%
“…Dexamethasone, an immunosuppressive corticosteroid, was given to all patients receiving Docetaxel in the FinHER trial (16). Although dexamethasone is a lymphodepleting agent, it is reported to have no significant impact on the clinical outcome of neoadjuvant TNBC patients retrospectively (54). Corticosteroid administration is not considered when characterizing treatment regimens during GEO dataset integration.…”
Section: Discussionmentioning
confidence: 99%